(Reuters) - Advisors to the U.S. Food and Drug Administration will meet on Thursday to discuss the relative risks and benefits of Baxter International Inc's experimental treatment for certain hereditary disorders of the immune system.

The FDA on Wednesday posted its preliminary assessment of the data on its website. The agency is seeking guidance from a panel of outside experts on whether the benefits of the product outweigh the risks. The FDA is not obligated to follow the recommendations of its advisors, but typically does so.